Chengdu Maximmune Pharmaceutical Technology Limited Liability Company (hereinafter referred to as "Maximmune") is a joint venture established by Maxlife Vaccines LLC, Chengdu Maxhealth Biotechnology LLC, and Inner Mongolia Jinyuankang Bioengineering Co. Ltd. in August 2018. Maximmune, established in Chengdu High-tech Zone with registered capital of 7 million RenMinBi (RMB), is dedicated to the research and development, production, and commercialization of innovative vaccine adjuvants, thermostable formulations for freeze-dried vaccines, novel animal vaccines, and other biological products.